Note 5 - Certain Balance Sheet Accounts (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
|---|
| Notes Tables |
|
| Schedule Of Contract Royalty Asset [Table Text Block] |
| |
|
March 31,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(In thousands)
|
|
|
Short-term contract royalty asset
|
|
$ |
25,477 |
|
|
$ |
25,351 |
|
|
Long-term contract royalty asset
|
|
|
93,717 |
|
|
|
96,435 |
|
|
Total OMIDRIA contract royalty asset
|
|
$ |
119,194 |
|
|
$ |
121,786 |
|
|
| Schedule of Royalty Obligation, Financial Position [Table Text Block] |
| |
|
March 31,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(In thousands)
|
|
|
Short-term OMIDRIA royalty obligation
|
|
$ |
19,856 |
|
|
$ |
20,547 |
|
|
Long-term OMIDRIA royalty obligation
|
|
|
141,930 |
|
|
|
147,319 |
|
|
Total OMIDRIA royalty obligation
|
|
$ |
161,786 |
|
|
$ |
167,866 |
|
|
| Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] |
| |
|
March 31,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(In thousands)
|
|
|
Trade receivables, net
|
|
$ |
6,746 |
|
|
$ |
— |
|
|
OMIDRIA royalty receivables
|
|
|
5,104 |
|
|
|
6,443 |
|
|
Novo Nordisk receivable
|
|
|
90 |
|
|
|
3,724 |
|
|
Other receivables
|
|
|
92 |
|
|
|
750 |
|
|
Total receivables
|
|
$ |
12,032 |
|
|
$ |
10,917 |
|
|
| Property, Plant, and Equipment [Table Text Block] |
| |
|
March 31,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(In thousands)
|
|
|
Equipment under finance lease obligations
|
|
$ |
8,323 |
|
|
$ |
8,323 |
|
|
Laboratory equipment
|
|
|
3,744 |
|
|
|
3,744 |
|
|
Computer equipment
|
|
|
1,113 |
|
|
|
1,113 |
|
|
Office equipment and furniture
|
|
|
624 |
|
|
|
624 |
|
|
Total cost
|
|
|
13,804 |
|
|
|
13,804 |
|
|
Less accumulated depreciation and amortization
|
|
|
(12,275 |
) |
|
|
(12,036 |
) |
|
Total property and equipment, net
|
|
$ |
1,529 |
|
|
$ |
1,768 |
|
|
| Schedule of Accrued Liabilities [Table Text Block] |
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
|
2026
|
|
|
2025
|
|
|
|
|
(In thousands)
|
|
|
Employee compensation
|
|
$ |
9,741 |
|
|
$ |
10,348 |
|
|
Clinical trials
|
|
|
6,379 |
|
|
|
6,248 |
|
|
Contract research and development
|
|
|
2,900 |
|
|
|
5,773 |
|
|
Deferred income
|
|
|
2,819 |
|
|
|
2,473 |
|
|
Consulting and professional fees
|
|
|
2,243 |
|
|
|
2,406 |
|
|
Income taxes payable
|
|
|
1,146 |
|
|
|
1,146 |
|
|
Interest payable
|
|
|
1,961 |
|
|
|
616 |
|
|
Other accrued expenses
|
|
|
617 |
|
|
|
378 |
|
|
Total accrued expenses
|
|
$ |
27,806 |
|
|
$ |
29,388 |
|
|